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School of Chemistry, National University of Ireland Galway, Galway, IrelandABSTRACT XPA is an essential protein in the nucleotide excision repair (NER) pathway, in charge of recruiting the ERCC1-
XPF endonuclease complex to the DNA damage site. The only currently available structural insight into the binding of XPA to
ERCC1 derives from the solution NMR structure of a complex between the ERCC1 central fragment and a 14-residue peptide,
corresponding to the highly conserved binding motif of the XPA N-terminus, XPA67-80. The extensive all-atom molecular-
dynamics simulation study of the XPA67-80 peptide both bound to the ERCC1 central fragment and free in solution presented
here completes the profile of the structural determinants responsible for the ERCC1/XPA67-80 complex stability. In addition to
the wild-type, this study also looks at specific XPA67-80 mutants in complex with the ERCC1 central domain and thus contributes
to defining the conformational determinants for binding, as well as all of the essential structural elements necessary for the
rational design of an XPA-based, ERCC1-specific inhibitor.INTRODUCTIONPlatinum drugs are currently the most potent chemothera-
peutic agents used to treat most types of cancer. The
progenitor of all platinum drugs, cis-diamminedichloropla-
tinum(II) (cis-DDP or cisplatin), was discovered in
1965 (1) and today is still one of the most effective drugs
in chemotherapy. Unfortunately, its efficacy is not the
same for all types of cancer: although it is extremely suc-
cessful in the treatment of testicular cancer, resulting
in >90% of complete recoveries, for most other tumors
the success rate decreases dramatically. In particular, in
ovarian cancer the tumor response to cisplatin is very
poor, with a 5-year survival rate of only 48% (GLOBOCAN
2008, http://globocan.iarc.fr). One of the main causes of the
failure of cisplatin is intrinsic or acquired resistance to the
drug, with the latter causing relapse. The efficacy of
cisplatin and all platinum drugs hinges on their ability to
bind DNA irreversibly by forming cross-links that bend
and unwind the double helix (2). Intrastrand 1,2d[GpG]
cross-links are the most abundant platinum-DNA covalent
adducts and are probably the most effective for triggering
cell death (3). The nucleotide excision repair (NER)
pathway is principally responsible for recognizing and
excising all bulky DNA lesions. It involves >30 proteins,
three of which—the excision-repair cross-complementing
group 1 (ERCC1), Xeroderma pigmentosum group F
(XPF), and Xeroderma pigmentosum group A (XPA)—are
essential for the removal of platinum-DNA adducts (4).
Indeed, it is known that ERCC1, XPF, and XPA are overex-
pressed in most platinum-resistant cancer cells (2,4,5),
which suggests an increased DNA repair activity. EnhancedSubmitted November 20, 2012, and accepted for publication April 10, 2013.
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0006-3495/13/06/2503/9 $2.00levels of ERCC1 have been directly linked to clinical resis-
tance to platinum chemotherapy (6,7). Conversely, these
enzymes are expressed at very low levels in testicular cancer
cells, which are very sensitive to cisplatin (2,5). Recent
work indicates that downregulation (8) or suppression (9)
of the XPF-ERCC1 endonuclease enhances the efficacy of
cisplatin. Additionally, mutations in XPA that inhibit its
interaction with ERCC1 directly hinder DNA repair
(10,11), most likely because XPA is known to recruit the
ERCC1-XPF complex to the DNA damage site so that the
repair can proceed (12,13).
XPA has a structurally well-characterized zinc-finger
central domain (sequence shown in black in Fig. 1)
comprising residues 98–219 (14). The ERCC1-binding
N-terminus includes residues 1–84 and is known to be
poorly structured in solution (14–17). Experimental evi-
dence shows that the 14-amino-acid sequence (shown in
red in Fig. 1) between Lys-67 and Glu-80 comprises all
the essential residues necessary for binding the ERCC1-
XPF endonuclease (10,15). A 14-residue peptide with the
same sequence, XPA67-80, was shown not only to bind
ERCC1 but also to inhibit its interaction with XPA (15).
Li et al. (10) investigated the role of two small fragments
of the XPA-binding sequence by means of mutagenesis and
in vitro binding assays. Their results show that deletion of
the Gly-72 to Phe-75 region, also known as the G motif,
abolishes binding to ERCC1 completely, whereas deletion
of the Glu-78 to Glu-84 region, or E motif, reduces binding
by ~70% (10). Additionally, XPA mutants lacking the
G motif were found to be unable to confer UV resistance
to the cells (10).
Because the ERCC1 binding domain of XPA is poorly
structured, there is a lack of structural information that
would allow us to identify the specific interactions that arehttp://dx.doi.org/10.1016/j.bpj.2013.04.023
FIGURE 1 XPA sequence (Homo sapiens). The zinc finger domain is
highlighted in black. The N- and C-termini are shown in gray above and
below the zinc finger domain sequence, respectively. The ERCC1-binding
region is shown in red.
2504 Faddacritical for binding. In a seminal work, Tsodikov et al. (15)
used a combination of NMR-derived distance restrains and
x-ray crystallography to determine the structure of the com-
plex between the central domain of ERCC1 and a synthetic
XPA67-80 peptide. In this complex, shown in Fig. 2, the
XPA67-80 peptide occupies a narrow pocket in the central
domain of ERCC1. The NMR data in this work highlight
only a limited number of hydrogen bonds and hydrophobic
contacts. Additionally, the resolution of the x-ray diffraction
data is too low to allow unequivocal identification of the
hydrogen-bonding network that holds the XPA67-80 peptide
in the ERCC1-binding site (15).
The inhibition of the interaction between XPA and
ERCC1-XPF binding was found to prevent the repair of
cisplatin-DNA adducts (11,15). Therefore, the development
of high-affinity synthetic ERCC1-XPF substrates can be
explored as an avenue to counteract resistance to platinumFIGURE 2 Solution NMR structure of the ERCC1-XPA67-80 complex
(PDBid 2JNW). The position of the residues represented with sticks is given
for all 10 structures deposited in the PDB. SER142 is not labelled for clarity
purposes and it is shown in yellow. The XPA67-80 peptide is shown in red on
panel a and in complex with the ERCC1 central domain (shown in grey) on
panel b.
Biophysical Journal 104(11) 2503–2511chemotherapy. The rational design of a competitive inhibi-
tor of the XPA/ERCC1-XPF interaction hinges on the iden-
tification of the structural and dynamics determinants for
binding. The aim of this study was twofold: 1), to highlight
the structural and dynamic features that contribute to the sta-
bility of the complex between the XPA67-80 section and the
ERCC1 central domain; and 2), to determine the degree of
disorder versus order in the XPA67-80 peptide free in solution
and how the conserved residues might influence the propen-
sity of the peptide secondary structure. Each of these themes
was addressed by extended MD simulations and analyzed
in view of the available NMR, crystallographic, and muta-
genesis data (10,11,15). The insights gained regarding the
essential structural and conformational determinants for
ERCC1/XPA67-80 binding are discussed in the following
sections.MATERIALS AND METHODS
To characterize both the structure and dynamics of the ERCC1-XPA67-80
complex, I conducted an extended molecular-dynamics (MD) simulation
study of the XPA67-80 peptide, both free and in complex with the ERCC1
central domain.
The conformational dynamics of the free XPA67-80 peptide in water was
monitored for 10 ms. The XPA67-80 peptide was built with version 4.0.1 of
ArgusLab (18) in a fully extended conformation, i.e., f ¼ j ¼ 180, with
sequence KIIDTGGGFILEEE, corresponding to the section K67-E80 of
the human XPA shown in Fig. 1 (NCBI Reference Sequence:
NP_000371.1). The peptide terminal residues were capped with acetyl
(ACE) and N-methylamide (NME) groups. The extended peptide was
inserted into a cubic simulation box with 70 A˚ sides. To reach neutrality,
three Naþ counterions were added to the system with the genion tool avail-
able in version 4.0.7 of the GROMACS simulation package (19). The posi-
tion of the water molecules and counterions was minimized with 50,000
steps of the steepest-descent algorithm, and then equilibrated for 500 ps
in the NVT ensemble, followed by 500 ps in the NPT ensemble with
T ¼ 300 K and p ¼ 1 bar as target values. The peptide was released
from all position restraints and equilibrated in the NPT ensemble for 1 ns
before a 50 ns production run. From this production run, 10 snapshots
(one every 5 ns) were collected (see Fig. S1 in the Supporting Material).
Each one of these snapshots was inserted into a new, smaller (48 A˚ sides)
cubic simulation box. Each snapshot was first minimized and then equili-
brated by following the same protocol used in the initial simulation. The
production run for each snapshot was extended to 1 ms, for a total of
10 ms MD simulation.
The role of specific residues in the stability of the ERCC1/XPA67-80 com-
plexwas analyzed through a series of 500 nsMD simulations involvingwild-
type (WT) and twomutant XPA67-80 peptides (F75A andD70A) bound to the
ERCC1 central domain. The first one of the 10 structures deposited in the
Protein Data Bank (PDB) with PDB ID 2JNW (15) was used as starting
structure (or template in the case of the XPA67-80 mutants) for all MD simu-
lations of the complex. The relative root mean-square deviation (RMSD) for
all heavy atoms in the XPA67-80 peptide calculated for the 10 structures
deposited in the PDB is 0.4 A˚, and the backbone RMSD is 0.2 A˚. The
PDB structure includes the Lys-67 to Leu-77 section of the XPA peptide
and the ERCC1 central domain, i.e., from Asn-99 to Ala-214. The residues
considered in all of the MD simulations match the PDB 2JNW structure
(i.e., to avoid the introduction of conformational biases, residues Glu-78,
Glu-79, and Glu-80 were not added). In the PDB structure (15),
His-149ERCC1 is protonated at Nd1. To thoroughly investigate the role of
the hydrogen bond between Asp-70XPA and His-149ERCC1 in the stability
of the complex, all MD simulations of the WT and F75A mutant XPA67-80
FIGURE 3 WT XPA67-80 backbone RMSD relative to the starting struc-
ture calculated over the 500 ns MD simulation of the ERCC1-XPA67-80
Structure and Dynamics of the XPA ERCC1-Binding Motif 2505were also runwithHis-149ERCC1 protonated atNε2. For the complexwith the
D70A XPA67-80 mutant, only the Nd1 protonation state was considered,
because the mutated Asp-70 is His-149ERCC1 hydrogen-bonding partner.
The following protocol was used for all five MD simulations: All missing
hydrogen atoms were added to the PDB structure. In the case of the mutants,
the side-chain atomsweremanually removed up toCb. The terminal residues
of both ERCC1 andXPAwere cappedwith ACE andNMEgroups. The com-
plex was centered in a cubic box built so that the minimum distance between
the protein and the side of the simulation boxwas 13 A˚. TwoCl counterions
were added to the complexes with WT and the F75A XPA67-80 mutant to
reach neutrality, and three Cl counterions were added to the complex
with the D70AXPA67-80 mutant. The positions of all water molecules, coun-
terions, and hydrogen atoms were optimized through 100,000 steps of steep-
est descent and then equilibrated in the NVT ensemble for 500 ps at 300 K.
The solvent, hydrogen atoms, and counterions were then equilibrated for
another 500 ps in the NPT ensemble at 300 K and 1 bar. The side chains of
the ERCC1 central domain were then released from the position restraints
and the system was equilibrated for 1 ns. Another equilibration phase of
1 ns followed, during which the side chains of the XPA67-80 peptide were
also released from all position restraints. During the last equilibration phase,
only the Ca atoms of the ERCC1 central domainwere kept restrained and the
system ran for 5 ns. The conformational dynamics of each one of the five
complexes was extended to 500 ns. The temperature was held constant at
300 K by a Langevin thermostat (20) with coupling time constant of
0.1 ps. A Berendsen barostat (21) was used to hold the pressure constant at
1 bar, with a time constant of 0.5 ps. All MD simulations were performed
with version 4.0.7 of the GROMACS software package (19). The equations
of motion were integrated using a leapfrog stochastic dynamics integrator
(22) with a 2 fs timestep. The linear constraint solver (LINCS) was used to
constrain all bonds with hydrogen atoms (23). Long-range electrostatics
were treated with the particle mesh Ewald (PME) method (24,25). The
maximum spacing for the fast Fourier transform (FFT) grid was chosen as
1 A˚. Cutoff values for Coulomb were set to 12 A˚, and van der Waals interac-
tions were switched off between 10 and 11 A˚.
The AMBER99SB force field (26) was chosen for all of the MD simula-
tions discussed in this work to represent the protein and ion atoms. MD
simulations of strong electrolyte (1:1) solutions have shown that the
adjusted A˚qvist parameters for ions used in the Amber99 force field suffer
from several shortcomings and can produce simulation artifacts, such as the
formation of ion insoluble aggregates in alkali chlorides below their solubi-
lity limit (16,27). No unphysical behavior of the counterions was observed
during the simulations discussed in this work. TIP3P (28) was selected as
the water model. The superiority of four- and five-site water models relative
to TIP3P in terms of the accuracy of water-binding free-energy calculations
was discussed in an earlier work (29). TIP3P originally was chosen as a
water model in this work because of its complementarity to the chosen
protein force field (30–32). A large portion of the MD simulations
discussed here were started before the work by Fadda and Woods (29)
was published.
Structure clustering was performed with the program g_cluster included
in version 4.0.7 of the GROMACS simulation package. Clusters were iden-
tified by means of the GROMOS algorithm (33). Based on the RMSD anal-
ysis of the trajectories of both free and bound peptide, an RMSD cutoff of
1.5 A˚ was chosen because it allowed the most significant conformational
transitions to be captured. Clustering data obtained with cutoff radii ranging
from 2.5 to 1.0 A˚ were collected for the bound peptide and are shown in
Table S1. A least-squares fit was performed over all rotational and transla-
tional degrees of freedom.
complex. The black line shows the RMSD of the complex where His-
145ERCC1 is protonated at Nε2 (HIE), and the red line shows the RMSD
of the complex where His-145ERCC1 is protonated at Nd1 (HID). The first
5 ns of the trajectory have been discarded as part of the equilibration phase.
(a and b) The first five conformations identified through clustering analysis
of the bound XPA67-80 peptide in the (a) HIE and (b) HID complexes. The
peptide backbone is shown in red for cluster 1, purple for cluster 2, green for
cluster 3, orange for cluster 4, and cyan for cluster 5.RESULTS
WT XPA67-80 bound to the ERCC1 central domain
The stability of specific interactions between the WT
XPA67-80 and the ERCC1 central domain was assessedduring the course of two separate MD simulations: one
with His-149ERCC1 protonated at Nε2 and one with
His-149ERCC1 protonated at Nd1. In the original PDB struc-
ture, His-149ERCC1 is protonated at Nd1 (see Fig. 2 b). How-
ever, the MD simulation results show that the hydrogen
bond between Asp-70XPA and His-149ERCC1 cannot form
when His-149ERCC1 is protonated at Nd1, because the latter
is always too far away from the carboxylic acceptor group.
The inability to form this hydrogen bond may affect the
complex’s conformational stability, ultimately biasing the
simulation results.
In the complex with His-149ERCC1 protonated at Nε2, the
XPA67-80 peptide fills the binding pocket stably throughout
the trajectory (see Fig. 3). The peptide backbone average
RMSD relative to the NMR complex calculated throughout
the trajectory after aligning just the ERCC1 central domains
is 4.7 A˚. The conformational dynamics of the peptide
involves mostly the peptide section between residues
Lys-67XPA and Gly-73XPA, which is one of the sections of
the peptide that is directly in contact with the solvent. The
clustering analysis allows to identify 15 different conforma-
tions occurring during the MD simulation, with only clusters
1–3 having a relative population larger than 10% (see
Table 1 and Fig. 3 a). The backbone RMSDs calculated
for each cluster relative to the NMR bound XPA67-80 peptide
are indicated in parentheses in Table 1.
The MD simulation highlights a network of hydrogen
bonds and hydrophobic contacts that contributes to stabilize
the complex. The carboxylate group of Asp-70XPA
forms hydrogen bonds with both the protonated Nε2 ofBiophysical Journal 104(11) 2503–2511
TABLE 1 Clustering analysis results obtained with an RMSD cutoff value of 1.5 A˚
Clusters WT HIE (15) WT HID (18) D70A (18) F75A HIE (14) F75A HID (26)
Cluster 1 43.6% (1.5) 48.7% (1.5) 67.1% (1.3) 39.8% (1.1) 61.6% (3.9)
Cluster 2 18.5% (1.5) 9.8% (1.7) 6.0% (4.6) 16.2% (1.6) 6.0% (3.4)
Cluster 3 11.1% (2.2) 9.5% (3.1) 4.0% (1.8) 10.4% (0.9) 4.0% (5.0)
Cluster 4 5.1% (2.7) 6.0% (1.8) 3.1% (1.1) 8.0% (2.5) 3.6% (4.0)
Cluster 5 3.6% (1.8) 4.5% (2.7) 2.5% (2.1) 5.6% (1.6) 3.3% (1.5)
The total number of clusters obtained from the analysis of each complex is indicated in parentheses in the first row. HIE indicates that His-149XPA is pro-
tonated at Nε2, and HID indicates that His-149XPA is protonated at Nd1. The backbone RMSD (in A˚) calculated for the middle structures of each cluster
relative to PDB 2JNW is shown in parentheses beside the cluster populations. Cluster populations above 10.0% are highlighted in bold.
2506 FaddaHis-149ERCC1 and the hydroxyl group of Tyr-145ERCC1.
These two hydrogen-bond interactions occur at different
times (Fig. S1) but are also seen to form concurrently. The
hydrogen bond between the Gly-74XPA backbone carboxylic
group and the Ser-142ERCC1 backbone amide nitrogen, also
identified by NMR (15), remains stable throughout the
trajectory, together with the hydrogen bond between
the Gly-73XPA backbone carbonyl group and the
Gln-107ERCC1 side-chain amide group, and the hydrogen
bond between the Gly-72XPA backbone carbonyl and the
Arg-156ERCC1 side chain. The hydrophobic stacking
between the Phe-75XPA and Asn-110ERCC1 side chains is
conserved throughout the trajectory. A summary of all stable
direct interactions identified during the MD simulation is
shown in Fig. 4. Also in agreement with the analysis of
the NMR data (15), the MD simulation also shows that
the Ile-68XPA side chain fills a hydrophobic pocket on the
side of the ERCC1-binding site, with an average RMSD
of 2.1 A˚ relative to the starting structure. Another interesting
hydrophobic interaction is the one involving His-149ERCC1,
Tyr-145ERCC1, and Tyr-142ERCC1 (Fig. 2). These side chains
are often found stacked, and such an interaction orients the
side chains of both Tyr-145ERCC1 and His-149ERCC1 in
an ideal position to form hydrogen contacts with the
Asp-70XPA carboxylate.
The MD simulation of the WT complex with the
His-149ERCC1 protonated at Nd1 shows that the hydrogen
bond between His-149ERCC1 and Asp-70XPA cannot form
due to the longer distance between the donor and the
acceptor. This results in the peptide being partially unbound
and conformationally disordered for the first 150 ns (Fig. 3).
As Asp-70XPA forms a stable hydrogen bond with theFIGURE 4 Contact map showing the most stable direct interactions iden-
tified throughout the 500 ns MD of the WT complex with H149ERCC1 pro-
tonated at Nε2. The XPA67-80 peptide residue IDs are shown in a box in
which the background color indicates the part of the peptide that is in con-
tact with the solvent (blue) and the part of the peptide that is buried in the
binding pocket (red).
Biophysical Journal 104(11) 2503–2511Tyr-145ERCC1 hydroxyl group, the peptide folds back into
the binding site, where it remains stable until the end of
the simulation. The clustering algorithm identifies 18 clus-
ters, with cluster 1 being the most populated conformation
at 49% (see Table 1). Clusters 1 and 2 are populated only
after the formation of the stable hydrogen bond between
Tyr-145ERCC1 and Asp-70XPA.D70A XPA67-80 bound to the ERCC1 central
domain
The simulation of the D70A XPA67-80 mutant is aimed
at defining the role of the hydrogen bond between
Asp-70XPA and His-149ERCC1 and/or Tyr-145ERCC1 in the
stability of the complex. The results are qualitatively similar
to those obtained for the WT complex with His-149ERCC1
protonated at Nd1. Indeed, as shown in Fig. 5, during the
first 150 ns of the simulation, the XPA67-80 D70A mutant
is conformationally disordered and partially unbound.
Again, the disorder is largely localized on the peptide
section between Lys-67XPA and Gly-73XPA in contact
with the solvent (see Fig. 4). After this time frame, the
conformational stability is regained and then maintainedFIGURE 5 The backbone RMSD value of the D70A mutant of XPA67-80
bound to the ERCC1 central domain is shown in black. The RMSD of the
complex with the WT XPA67-80 where His-149ERCC1 is protonated at Nε2 is
shown in red for comparison. All RMSD values are relative to the starting
structure (PDB ID: 2JNW). The middle structures of the first five most-
populated clusters are shown in the upper-right corner.
Structure and Dynamics of the XPA ERCC1-Binding Motif 2507until the end of the trajectory. The clustering algorithm iden-
tifies 18 different conformations visited during the 500 ns
MD (the first five are shown in Fig. 5 a). Cluster 1 is largely
the most populated and represents the only conformational
ensemble visited in the time frame between 150 and
500 ns. This stable conformation is characterized by internal
hydrogen bonds between the peptide backbone atoms, i.e.,
Phe-75XPA and Thr-71XPA, and Leu-77XPA and Ile-69XPA.
Other stable hydrogen bonds are formed between the
His-149ERCC1 Nε2 and the hydroxyl group of Thr-71XPA,
and between the Tyr-145ERCC1 and the Thr-71XPA backbone
carbonyl. All other stable interactions identified previously
for the WT complex are also maintained here, i.e., the stack-
ing between Phe-75XPA and Asn-110ERCC1, the hydrogen
bond between the Gly-74XPA backbone carbonyl and the
Ser-142ERCC1 backbone amide nitrogen, and the hydrogen
bond between the Gly-73XPA backbone carbonyl and the
Gln-107ERCC1 side-chain amide group (see Fig. 4). Addi-
tionally, the nonspecific hydrophobic contact between
Ile-76XPA and the hydrophobic pocket at the mouth of the
ERCC1 binding site is also conserved.F75A XPA67-80 bound to the ERCC1 central
domain
The role played by the stacking interaction between
Phe-75XPA and Asn-110ERCC1 in the conformational stabil-
ity of the complex was assessed by means of two separate
MD simulations: one with His-149ERCC1 protonated at
Nε2 and one with His-149ERCC1 protonated at Nd1. The
average backbone RMSDs relative to the NMR structure
calculated throughout both simulations are shown in
Fig. 6. The results clearly indicate that the XPA67-80 peptideFIGURE 6 Backbone RMSD of the F75A mutant of XPA67-80 bound to
the ERCC1 central domain. The RMSD of the complex with His-149ERCC1
protonated at Nε2 is shown in black, and the RMSD of the complex with
His-149ERCC1 protonated at Nd1 is shown in red. All RMSDs are calculated
relative to the corresponding starting structure. (a and b) Snapshots were
collected every 2.5 ns of the F75A XPA67-80 mutant in complex with
ERCC1, with His-149ERCC1 protonated at (a) Nε2 or (b) Nd1.is less conformationally disordered when bound to ERCC1
with His-149ERCC1 protonated at Nε2. The clustering anal-
ysis for this complex (see Table 1) identifies only three clus-
ters populated more than 10%. During the first 100 ns of the
simulation, the most populated conformational ensemble is
cluster 3. Such conformation is stabilized by internal
hydrogen bonds between the peptide backbone atom, i.e.,
between Gly-72XPA and Ala-75XPA, and Ile-69XPA and
Leu-77XPA, but among the interactions highlighted in
Fig. 4, it lacks other than the stacking between Phe-75XPA
and Asn-110ERCC1 due to the F75A mutation, the interaction
between Arg-156ERCC1 and Gly-72XPA, and any interaction
involving Asp-70XPA. Indeed, Tyr-145XPA is involved in an
interaction with the amide backbone atom of Gly-74XPA,
and His-149ERCC1 is not involved in any hydrogen bonding
throughout the entire trajectory but remains stacked to the
Tyr-145XPA side chain. Clusters 1 and 2 become populated
after the initial 70 ns and are characterized by the forma-
tion of stable hydrogen bonds between Tyr-145XPA and
Asp-70XPA, and Arg-156ERCC1 and Gly-72XPA, which last
throughout the remainder of the trajectory.
As shown in Fig. 6, the peptide in complex with ERCC1
with His-149ERCC1 protonated at Nd1 shows the highest
degree of disorder among all the complexes studied in this
work. The clustering analysis summarized in Table 1 iden-
tifies 26 different conformations visited during the simula-
tion, with only cluster 1 significantly populated at 62%.
The middle structures for the first five clusters are shown
in Fig. 6 b. All of these conformations are characterized
by a large distance between the two sides of the hairpin,
in contrast to the peptide in the other complexes. Indeed,
the XPA67-80 peptide is largely unbound throughout the sim-
ulations. Among the stable interactions identified and shown
in Fig. 4, only two hold throughout the trajectory: the one
between Ser-142ERCC1 and Gly-74XPA, and the one between
Gly-73XPA and Gln-107ERCC1. In contrast to all of the previ-
ous cases, neither Tyr-145ERCC1 nor His-149ERCC1 is
involved in any stable interaction with the peptide residues.XPA67-80 free peptide in solution
The conformational dynamics of the XPA67-80 peptide un-
bound in solution was also studied. From an initial trajectory
of 50 ns started from a fully extended peptide, 10 uncorre-
lated snapshots (one each every 5 ns) were selected. These
10 structures are shown in Fig. S2. The conformational
dynamics of each snapshot was monitored for 1 ms, for a
total of 10 ms MD simulation. The different snapshots are
seen to explore specific regions of the XPA67-80 conforma-
tional space. Based on the results of the clustering (see
Table 2) and conformational analyses (the latter in terms of
radius of gyration and RMSD), the XPA67-80 peptide in solu-
tion does not show any propensity to form a stable secondary
structure motif for ~52% of the total simulation time. The
radius of gyration calculated for each snapshot (shown inBiophysical Journal 104(11) 2503–2511
TABLE 2 Clustering analysis results obtained with an RMSD cutoff value of 1.5 A˚
Cluster sizes per snapshot Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5
s1 (172) 15.7% (3.4) 13.1% (2.3) 7.4% (3.2) 4.1% (2.8) 3.4% (3.4)
s2 (238) 24.3% (2.4) 9.6% (3.7) 5.3% (2.8) 2.7% (3.6) 2.5% (3.3)
s3 (36) 47.7% (3.7) 24.3% (2.6) 8.2% (1.9) 5.6% (3.9) 3.9% (2.6)
s4 (113) 45.3% (2.8) 4.1% (4.4) 3.2% (4.1) 3.2% (5.1) 3.0% (4.4)
s5 (186) 17.8% (2.4) 8.6% (4.1) 7.4% (3.2) 3.4% (2.4) 3.0% (2.3)
s6 (3) 93.6% (2.4) 5.9% (2.4) 0.6% (3.1)
s7 (8) 90.0% (2.4) 4.0% (2.8) 3.7% (2.4) 1.6% (2.1) 0.3% (3.4)
s8 (13) 92.7% (2.5) 3.0% (2.7) 0.9% (3.9) 0.8% (3.1) 0.7% (2.2)
s9 (230) 18.3% (3.9) 15.7% (3.4) 7.9% (2.4) 5.2% (2.4) 3.7% (3.3)
s10 (146) 23.1% (2.6) 10.8% (4.1) 5.8% (3.1) 5.5% (4.2) 2.7% (5.5)
The total number of clusters obtained from the analysis of each snapshot is indicated in parentheses in the first column. The relative population and the back-
bone RMSD (in A˚) of the middle structure relative to the NMR 2JNW structure are shown for the five highest-populated clusters. Clusters with populations
larger than 10.0% are highlighted in bold.
2508 FaddaFigs. S3 and S4) indicates that during this time frame the
peptide extends and recoils, forming very short-lived struc-
tures. These unstable conformations are usually held
together by one or two hydrogen bonds, typically involving
terminal residues. For the remaining 48% of the simulation
time, the peptide forms different stable hairpin-like struc-
tures (see Fig. 7). The relative populations of these structures
and their backbone RMSDs relative to the bound peptide
from NMR are shown in Table 2. The highest-populated
clusters obtained from analysis of the simulations of snap-
shots 2, 5, and 6–8 correspond to the same hairpin conforma-
tion. The alignment of the clusters’ middle structures, with
an average backbone RMSD of 0.4 A˚, is shown in Fig. S5.
As shown in Table 2, this hairpin has an average backbone
RMSD of 2.4 A˚ relative to the bound NMR conformation,
and based on the clustering analysis is stable for >3.1 ms.FIGURE 7 Stable hairpin motifs identified through clustering analysis
during the 10 ms simulation of the XPA67-80 peptide free in solution. The
structure of the bound peptide from the NMR structure 2JNW is shown
as a reference in cyan. Each panel shows the middle structure from the high-
est-populated clusters identified during the simulations (see Table 2). The
highest-populated clusters are shown in red and the second highest-popu-
lated clusters are shown in purple. Only clusters with a relative population
larger than 10.0% are shown. (a–h) Clusters from (a) snapshot 1, (b) snap-
shot 2, (c) snapshot 3, (d) snapshot 4, (e) snapshot 5, (f) snapshots 6–8,
(g) snapshot 9, and (h) snapshot 10.
Biophysical Journal 104(11) 2503–2511This stability depends on the formation of three hydrogen
bonds between the backbone atoms of Ile-68 and Leu-77,
Asp-70 and Gly-74, and Asp-70 and Phe-75. Snapshot 3
shows two stable hairpin conformations with relative popu-
lations of 48% and 24%, respectively (see Fig. 7 c). As
shown in the RMSD plots in Fig. S6 c, cluster 1 forms during
the first half of the simulation and cluster 2 forms during
the second half. Snapshot 4 also shows a stable hairpin
(Fig. 7 d). This structure remains stable for 48% of the simu-
lation time (Table 2) and is held together by three hydrogen
bonds: one between the backbone atoms of Asp-70 and
Phe-75, and two between Ile-68 and Leu-7. The same motif
is also the highest-populated one during the simulation of
snapshot 10 (Fig. 7 h). The relative backbone RMSD
between the highest-populated clusters from snapshots
4 and 10 is 0.8 A˚. This hairpin is held by three hydrogen
bonds between Ile-68 and Leu-77, Asp-70 and Phe-75, and
Asp-70 and Gly-73 (Fig. 7 h). Based on the clustering anal-
ysis, this structure is stable for 684 ns. The backbone RMSD
obtained from alignment of the middle structures represen-
tative of the most stable and second-most stable hairpin
formed by the XPA67-80 peptide free in solution is 1.8 A˚.DISCUSSION
Sequence alignment shows that the XPA sequence between
residues 67 and 80 (XPA67-80) is highly conserved, with very
few exceptions (10,11,34). Highly conserved residues can
form essential interactions in the binding site and/or control
the conformational propensity of the peptide free in solu-
tion. The latter determines the presentation of the peptide
to its receptor upon binding.
The simulations of the ERCC1 in complex with WT and
mutant XPA67-80 peptides presented in this work allow for
the identification of all nonbonded interactions that are crit-
ical for the stability of the complex. These interactions are
summarized in Fig. 4 and include both hydrogen bonds and
hydrophobic contacts. The stability of all of the hydrogen-
bonding interactions highlighted from the analysis of the
NMR data (15), i.e., the hydrogen bond between the
Structure and Dynamics of the XPA ERCC1-Binding Motif 2509backbone atoms of Gly-74XPA and Ser-142ERCC1, and
between the side chains of Asp-70XPA and His-149ERCC1, is
confirmed by the MD simulations. A critical but previously
unidentified hydrogen bond was ubiquitous in all of the sim-
ulations. This bond forms between the Gly-73XPA backbone
carbonyl and the Gln-107ERCC1 amide side chain, and stabi-
lizes the position of the XPA67-80 hairpin central loop.
In addition to these interactions, the simulations suggest
that Asp-70XPA is often involved in a stable hydrogen
bond with the side chain of Tyr-145ERCC1. The key role of
Tyr-145ERCC1 in the stability of the complex is shown by
the analysis of the MD simulations of all complexes. Indeed,
both simulations of the complex with the WT XPA67-80,
independently of the protonation state of His-149ERCC1,
indicate that the formation of a hydrogen bond between
Asp-70XPA and Tyr-145ERCC1 restores the conformational
stability of the bound peptide (Fig. 3). Additionally, in the
simulations of the complexes with the D70A and F75A
XPA67-80 mutants, the hydrogen-bonding interactions
involving Tyr-145ERCC1 are crucial for the return of the pep-
tide to a bound conformation (Figs. 5 and 6). As shown in
the simulation of the complex with the F75A XPA67-80
mutants and with the His-149ERCC1 protonated at Nd1, the
inability of His-149ERCC1 and Tyr-145ERCC1 to interact
with any hydrogen-bond acceptors on the solvent-exposed
side of XPA67-80 causes the peptide to remain partially
unbound throughout the simulation. This crucial structural
role played by Tyr-145ERCC1 in the stability of the complex
is in agreement with experimental evidence (11) that shows
a significantly diminished NER activity of the Y145A
ERCC1 mutant, most likely due to its inability to bind XPA.
The MD results also show that the His-149ERCC1,
Tyr-145ERCC1, and Tyr-152ERCC1 side chains are often
found stacked. This stacking interaction orients the residue
side chains so that both His-149ERCC1 and Tyr-145ERCC1 can
interact with the section of the peptide in contact with the
solvent. The possibility of a relative reorientation of the
His-149ERCC1, Tyr-145ERCC1, and Tyr-152ERCC1 side chains
is also supported by the structural data (15) and, as shown in
Fig. 2, such an orientation can be observed directly from the
alignment of the 10 structures deposited in the PDB.
The main hydrophobic interactions that XPA67-80 forms
in the ERCC1 binding site are the stacking between
Phe-75XPA and Asn-110ERCC1 and the nonspecific contact
between the Ile-67XPA side chain and the side of the binding
pocket (Fig. 2). The mutation of Phe-75XPA to Ala was cho-
sen for comparison with functional assays showing that the
F75A mutant completely abolished binding and thus NER
activity (15). The simulations show that the F75A mutation
does not significantly affect the orientation of the
Asn-110ERCC1 side chain or the position of the section of
peptide that is in contact within the interior of the binding
pocket. This may be due to the tight packing of the peptide
in the binding pocket, as well as the hydrogen bond and
hydrophobic interactions being sufficient to hold that sec-tion in place during the time frame of the MD analyzed.
Moreover, the structural complementarity is most likely
only one of the contributing factors behind the critical role
of Phe-75XPA in binding. Nevertheless, as shown by the
simulation of the complex with the F75A XPA67-80 mutant
with His-149ERCC1 protonated at Nd1, the lack of a stacking
interaction between Phe-75XPA and Asn-110ERCC1, together
with the absence of the hydrogen bonds involving either
His-149ERCC1 or Tyr-145ERCC1, results in the most confor-
mationally unstable complex. This result is in agreement
with previous experimental data (11) showing the inability
of both the single N110A and double A110A/Y145A
ERCC1 mutants to bind XPA.
In agreement with heteronuclear single quantum correla-
tion (HSQC) NMR data (15), the conformational dynamics
of the XPA67-80 free in solution shows a high degree of dis-
order. This work demonstrates the ability of the peptide to
form stable secondary structure motifs. As shown in
Fig. 7, these motifs are prevalently b-strand turns and hair-
pins stabilized by a minimum of three hydrogen bonds
involving backbone atoms. The most populated hairpin
conformation identified is shown in Fig. 7, b, e, and f, and
is stable for slightly more than 3.1 ms, or ~1/3 of the total
simulation time. The intrinsic propensity to form narrow
hairpins, which are quite similar to the bound structure
(see Fig. 7), could play a role in the presentation and recog-
nition of the peptide by ERCC1. Although the relative sta-
bility of secondary structure motifs can be affected by the
choice of force field, the diversity and reoccurrence of the
same structural motifs seen in these extensive MD simula-
tions suggest that the highly conserved XPA67-80 sequence
may determine the preference for a particular fold. More
specifically, in the complex with ERCC1, three consecutive
glutamates (Glu-78XPA, Glu-79XPA, and Glu-80XPA) and on
the opposite end of the peptide a lysine (Lys-67XPA) are
located outside of the binding pocket. The available struc-
tural data (15) indicate that the sections of XPA outside of
the binding pocket are quite disordered. Nevertheless, all
three glutamates are highly conserved and their deletion
has been shown to reduce binding significantly (10). The
analysis of the MD simulations of the free peptide in solu-
tion suggests that the favorable electrostatic interaction
between these highly conserved residues with opposite
charge located at both ends of the peptide can contribute
to the propensity to form hairpins. Moreover, small flexible
residues, such as the three glycines located in the center of
the XPA67-80 peptide, would also favor a hairpin conforma-
tion. Indeed, deletion of the G motif, which includes two of
these glycines (Gly-73XPA and Gly-74XPA) and Phe-75XPA,
has been shown to eliminate binding completely (10).CONCLUSIONS
NMR and crystallographic data (15) highlight a number
of specific interactions that the XPA67-80 peptide formsBiophysical Journal 104(11) 2503–2511
2510 Faddawith the ERCC1 central domain. These involve almost
exclusively the section of the XPA67-80 peptide in contact
with the interior of the ERCC1-binding pocket. Based on
this evidence, the peptide section from Lys-67XPA to
Thr-71XPA that is exposed to the solvent does not appear
to form specific interactions with the ERCC1 central
domain. This study builds on these structural data (15)
and highlights all of the structural determinants that are
essential for the conformational stability of the complex
between the XPA67-80 peptide and the ERCC1 central
domain (Fig. 4). The key structural role of specific
residues, such as Tyr-145ERCC1 and His-149ERCC1, identi-
fied in this study is also supported by the results of
functional assays. Indeed, the highly diminished NER
activity of the single Y145A and double N110A/Y145A
mutants reported by Orelli et al. (11) is supported by the
critical role played by Tyr-145ERCC1 in the conformational
stability of the complex. Based on the data presented and
discussed in this work within the context of experimental
evidence, the design of a pharmacophore profile aimed
at identifying an ERCC1/XPA inhibitor is currently in
progress.
Furthermore, the clustering analysis of the extensive
conformational dynamics of the XPA67-80 peptide free in
solution points toward a definite propensity to form hairpin
motifs similar to the bound conformation (Fig. 7). This
intrinsic conformational preference may affect recognition
and ultimately binding by being a determinant factor in
the presentation of the peptide to the receptor. A conforma-
tional study focused on determining the propensity of spe-
cific XPA67-80 peptide mutants to form hairpin motifs is
also currently under way.SUPPORTING MATERIAL
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